Rising Development of Soliris Biosimilars Presents a Significant Opportunity in the Soliris Drug Market

Soliris drug market was valued at $2.5 billion in 2024 and is projected to reach $4.3 billion by 2035, growing at a CAGR of 5.2% during the forecast period (2025-2035). The growth is primarily propelled by potential cost savings and increased access to Biosimilars that are highly similar to the drug Soliris. Biosimilars offer a more affordable alternative solution, potentially reducing the overall cost of treatment for conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). This shift could lead to increased market penetration and wider availability of these crucial medications. 

Browse the full report description of “Soliris Drug Market Size, Share & Trends Analysis Report by Type (Plasma Exchange and Plasma Infusion), by Application (Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorder, and Other), Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/soliris-drug-market

Key Players and Innovations

Several major players lead the Soliris drug market, including Alexion Pharmaceuticals, Inc. (now part of AstraZeneca), Amgen Inc., and Samsung Bioepis Co., Ltd. These companies are at the forefront of innovation, constantly developing new technologies to meet the industry's evolving needs. These players assist in the market’s growth with the launch of new products and through collaborations and investments. Some of the recent developments in the market include-

• In March 2025, Amgen launched Bkemv (eculizumab-aeeb) in the US is the first available interchangeable biosimilar to Alexion’s Soliris. Bkemv was approved by the FDA in May 2024 for the same indications as Soliris (aHUS and PNH), and in the same dosage form and strength.

Market Coverage

• The market numbers available for – 2024-2035

• Base year- 2024

• Forecast period- 2025-2035 

• Segment Covered- 

o By Type

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape - Alexion Pharmaceuticals, Inc. (now part of AstraZeneca), Amgen Inc., and Samsung Bioepis Co., Ltd.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Soliris Drug Market Report Segment

By Type

• Plasma Exchange
• Plasma Infusion

By Application

• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Atypical Hemolytic Uremic Syndrome (aHUS) 
• Myasthenia Gravis
• Neuromyelitis Optica Spectrum Disorder
• Other

Global Soliris Drug Market Report Segment by Region

North America

• United States

• Canada 

Europe

• UK

• Germany

• Italy

• Spain

• France

• Russia

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Australia and New Zealand

• ASEAN Economies

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/soliris-drug-market